Spotlight On... Glaxo socks more cash into immunotherapy bet; Justice wants a bankruptcy trustee to take over KaloBios; CVS to roll out naloxone OTC in Ohio; and more...

Last year, GlaxoSmithKline ($GSK) traded away most of its cancer assets to Novartis ($NVS) in exchange for the majority of the Swiss drugmaker's vaccines portfolio. But it's not out of the area altogether, and now, it's sweetening a deal with oncology partner Adaptimmune. Glaxo has promised more cash to speed up development of a promising treatment for soft tissue sarcoma, pledging to fund pivotal trials for the immunotherapy. Read more from FierceBiotech

@FiercePharma: Roche expects April price cut for Avastin in Japan where Tamiflu sales also hit. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Don't expect a generics-style smackdown from Remicade biosims, J&J CEO says. Article | Follow @CarlyHFierce

> The controversial and bankrupt California-based biotech KaloBios Pharmaceuticals, briefly run by "pharma bro" CEO Martin Shkreli, needs to be taken over by an independent trustee, a Justice Department unit says. Report

> CVS Health ($CVS) says it will make the opioid antidote naloxone available over the counter in Ohio to help reduce overdose deaths. Report

> Allergy specialist Stallergenes Greer, based in London, has restarted production at a plant in France where operations had been suspended. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: IBM Watson, AHA and Welltok to develop workplace heart health program. Article | Follow @FierceMedDev

@VarunSaxena2: Updated w analyst info: Stryker to buy disposable device maker for $2.8B to reduce hospital-acquired infections. Report | Follow @VarunSaxena2

@EmilyWFierce: Roche sees no 'short term' pricing pressure for company's cancer drugs: Reuters. FiercePharma story | Follow @EmilyWFierce

> Med tech shops around for cost-cutting deals amid increased demand from hospitals. Report

> At Baxter, Covidien's Almeida looks to cut costs, fuel innovation and do smaller acquisitions. Story

> Swiss contract manufacturer diversifies into med tech via $895M acquisition of Creganna Medical. Article

Biotech News

@FierceBiotech: Backed by J&J and Glaxo, veteran VC group splits from Index, unveils $227M fund. Report | Follow @FierceBiotech

@JohnCFierce: Trending: Will Zika frenzy fuel an overnight vaccine R&D miracle? Don't bet on it. More | Follow @JohnCFierce

@DamianFierce: the only thing I miss about working at a newspaper is election night pizza. | Follow @DamianFierce

> GlaxoSmithKline up-sizes its bet on Adaptimmune, racing forward with a cancer immunotherapy. Story

> Sanofi chops into R&D operations in France in latest retrenchment. Article

> Glaxo, Atlas syndicate bankrolls Spero's drive into the clinic with $30M round. Report

Pharma Manufacturing News

> Troubled Sun Pharma manages U.S. launch of copy of blockbuster Gleevec. Report

> Teva U.K. plant cuts 80 jobs as drugmaker looks for higher skilled workers. News

> CDMO Vetter finishes IT upgrade at German facility. Story

> FDA hands Wockhardt and Ipca more disappointing news. Article

> Allergan CEO suggests expanded Texas plant may be in store for more jobs. More

Drug Delivery News

> Mercator launches microinfusion catheter trial for below-the-knee ischemia. More

> New CRISPR/Cas9 delivery method could offer a clinical pathway. Report

> FDA approves the first extended-release orally disintegrating tablet for ADHD. Item

> Dr. Reddy's wins approval for injectable generic to treat migraines. Story

> Aprecia completes $35M financing to support launch of the first 3-D printed medication. Article

Pharma Asia News

> BMS details new Japan hit to hep C sales. Item

> India's Sun Pharmaceutical meets Feb. 1 deadline for U.S. imatinib launch. More

> Management moves to take Nasdaq-listed Sinovac Biotech private in growing trend. Report

> China's Qiming's fifth U.S. dollar venture fund clocks in at $648 million in commitments. Story

> Amgen says it's awaiting reimbursement details after Japan Repatha nod. Article

And Finally... The internet in your head? The brain's capacity is 10 times greater than previously thought, a study found. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.